SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 207 filers reported holding SEATTLE GENETICS INC in Q4 2013. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $2,021,000 | +100.1% | 39,053 | +143.0% | 0.06% | +100.0% |
| Q1 2017 | $1,010,000 | -47.5% | 16,073 | -55.9% | 0.03% | -40.4% |
| Q4 2016 | $1,924,000 | +65.4% | 36,457 | +69.3% | 0.05% | +67.9% |
| Q3 2016 | $1,163,000 | +165.5% | 21,537 | +98.6% | 0.03% | +211.1% |
| Q2 2016 | $438,000 | -22.2% | 10,843 | -32.5% | 0.01% | -43.8% |
| Q1 2016 | $563,000 | -23.1% | 16,053 | -15.4% | 0.02% | +33.3% |
| Q3 2015 | $732,000 | +148.1% | 18,979 | +211.0% | 0.01% | +140.0% |
| Q2 2015 | $295,000 | -26.8% | 6,103 | -46.5% | 0.01% | -37.5% |
| Q1 2015 | $403,000 | -33.7% | 11,405 | -30.3% | 0.01% | -33.3% |
| Q3 2014 | $608,000 | +74.7% | 16,363 | +79.7% | 0.01% | +140.0% |
| Q2 2014 | $348,000 | -32.7% | 9,107 | -19.8% | 0.01% | -16.7% |
| Q1 2014 | $517,000 | +71.2% | 11,357 | +49.7% | 0.01% | +100.0% |
| Q4 2013 | $302,000 | -62.9% | 7,587 | -59.2% | 0.00% | -70.0% |
| Q3 2013 | $815,000 | – | 18,599 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |